Finance

Beta
Senarai
Sektor ekuiti
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Buka
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
HEAL:IDX
Medikaloka Hermina Tbk PT
IDR 1,150.00
-1.71%
(-20.00) 1H
30 Apr, 4:12:26 PTG GMT+7  ·   IDR
Semua simbol
SimbolPriceChange% Change
Generating top insights for HEAL...
Buka
IDR 1,170
High
IDR 1,205
Low
IDR 1,070
Mkt. cap
17.67T
Avg. vol.
10.44J
Volume
0.00
Dividend
1.17%
Quarterly dividend
IDR 3
Ex dividend date
5 Mei 2026
P/E ratio
40.49
52-wk high
IDR 1,775
52-wk low
IDR 1,070
EPS
IDR 28
Shares outstanding
15.26B
No. of employees
19K
News stories
From sources across the web
Profil
PT Medikaloka Hermina Tbk is a health service company headquartered in Jakarta, Indonesia. As of December 2024, the hospital network had grown to 52 hospitals operating in 63 cities across 17 provinces in Indonesia. Wikipedia
About Medikaloka Hermina Tbk PT
CEO-
Employees18.6K
Founded1985
Headquarters-
Sector-
Websiteherminahospitals.com
Last report
26 Mac 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-/ -IDR
Revenue / Estimate
1.85T/ (- est.)IDR
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in IDR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in IDR
Mac 2025
Jun 2025
Sep 2025
Dis 2025
Revenue
1.69T
1.70T
1.90T
1.85T
Cost of goods sold
1.14T
1.17T
1.29T
1.24T
Cost of revenue
1.14T
1.17T
1.29T
1.24T
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
226.02B
250.19B
264.88B
313.31B
Operating expense
284.75B
314.92B
327.65B
385.32B
Total operating expenses
1.43T
1.49T
1.62T
1.63T
Operating income
264.66B
209.25B
277.92B
216.71B
Other non operating income
-
-
-
-
EBT including unusual items
214.81B
151.71B
224.17B
164.20B
EBT excluding unusual items
215.26B
151.24B
224.90B
164.97B
Income tax expense
54.22B
27.99B
57.41B
66.30B
Effective tax rate
25.24%
18.45%
25.61%
40.38%
Other operating expenses
-8.00B
-6.07B
-6.38B
-6.72B
Net income
124.73B
100.12B
131.17B
73.53B
Net profit margin
7.37%
5.90%
6.91%
3.98%
Earnings per share
-
-
-
-
Interest and investment income
6.55B
9.96B
3.69B
6.08B
Interest expense
-55.95B
-67.97B
-56.70B
-57.82B
Net interest expenses
-49.40B
-58.01B
-53.02B
-51.74B
Depreciation and amortization charges
66.71B
70.66B
69.10B
72.88B
EBITDA
471.58B
424.68B
446.07B
424.70B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

Tugasan saya
Anda belum membuat tugasan lagi
Tugasan anda akan dipaparkan di sini. Jadualkan tugasan dan manfaatkan Google Finance semasa anda tiada.
Templat
Ringkasan senarai amatan
Analisis prapasaran harian bagi senarai amatan anda
Pendapatan Akan Datang
Laporan pendapatan akan datang dalam minggu ini
Kemudahubahan & Jumlah yang Tidak Normal
Amaran awal kemudahubahan dan jumlah hari ini
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer